Document Detail

The use of antiinflammatory therapy and macrolides in bronchiectasis.
MedLine Citation:
PMID:  22640852     Owner:  NLM     Status:  In-Data-Review    
Airway inflammation is a major component of disease pathogenesis in bronchiectasis, suggesting that antiinflammatory therapies could be of benefit in treatment. This article addresses the use of anti-inflammatory/immunomodulatory therapies in the management of patients with bronchiectasis and individually discusses the use of corticosteroids, macrolides, and other potential anti-inflammatory agents.
Charles Feldman
Publication Detail:
Type:  Journal Article     Date:  2012-03-31
Journal Detail:
Title:  Clinics in chest medicine     Volume:  33     ISSN:  1557-8216     ISO Abbreviation:  Clin. Chest Med.     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7907612     Medline TA:  Clin Chest Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  371-80     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Division of Pulmonology, Department of Internal Medicine, Faculty of Health Sciences, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, 7 York Road, Parktown 2193, Johannesburg, South Africa.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacologic agents for mucus clearance in bronchiectasis.
Next Document:  Antimicrobial therapy for bronchiectasis.